The global AI-based digital pathology market is expected to grow from USD 1.01 billion in 2025 to USD 2.32 billion by 2035, driven by a compound annual growth rate (CAGR) of 8.7%. This expansion is fueled by rapid technological advancements, the rising demand for precision medicine, and the increasing integration of artificial intelligence into clinical and research workflows. AI-powered digital pathology is transforming traditional histopathology by replacing conventional microscopy with digital slide analysis. The digitization of glass slides enables faster, more efficient transmission of data between diagnostic centers and pathologists, significantly improving the ability to analyze complex tissue micro-environments. By enabling more accurate, quantitative, and reproducible assessments, AI tools are helping to personalize treatment plans and enhance patient outcomes across a range of disease areas. Currently, around 80 companies worldwide offer AI-based digital pathology solutions, primarily serving research institutions, academic medical centers, and diagnostic laboratories. These companies develop proprietary AI platforms tailored for specific applications, including cancer detection, disease classification, and treatment response prediction. The market has seen strong investor interest, with approximately USD 2 billion raised across 60 funding events in recent years, underscoring confidence in the long-term potential of AI in pathology. The report provides a comprehensive analysis of the market, segmented by type of neural network, assay type, end-user (e.g., hospitals, research labs, pharmaceutical companies), area of application, and target disease indications such as oncology, neurology, and infectious diseases. It also includes a detailed regional breakdown, covering North America, Europe, Asia-Pacific, and other key geographies. Key players in the market include Aiforia Technologies, Ibex Medical Analytics, Indica Labs, PathAI, Roche, Visiopharm, and several emerging innovators. The report features in-depth company profiles, competitive landscape analysis, and insights into strategic moves such as partnerships, product launches, and funding activities. The market is also being shaped by increasing regulatory support, growing adoption in clinical settings, and the need for faster, more consistent diagnostic results. As AI models become more accurate and validated, their use in routine diagnostics is expected to expand, especially in high-volume environments like cancer screening programs. With a total of 212 pages, the report offers detailed forecasts, market sizing, and opportunity analysis, along with appendices containing tabulated data and a comprehensive list of companies. It is designed to help stakeholders—ranging from healthcare providers and technology developers to investors and policymakers—understand the evolving digital pathology landscape and identify strategic growth opportunities. The report is a valuable resource for anyone seeking to understand the current state and future trajectory of AI in pathology, highlighting the transformative role of technology in modern medicine.